Prognostic significance of early phase donor chimerism after allogeneic peripheral blood stem cell transplantation.
10.3760/cma.j.issn.0253-2727.2018.11.012
- Author:
Wei Hua ZHAI
1
;
Qing Zhen LIU
;
Yuan Yuan SHI
;
Gang LI
;
Jia Li SUN
;
Xin CHEN
;
Jian Feng YAO
;
Xiu Hua SU
;
Qiao Ling MA
;
Ai Ming PANG
;
Yi HE
;
Dong Lin YANG
;
Rong Li ZHANG
;
Yong HUANG
;
Jia Lin WEI
;
Si Zhou FENG
;
Ming Zhe HAN
;
Er Lie JIANG
Author Information
1. Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
- Publication Type:Journal Article
- Keywords:
Chimerism;
Hematopoietic stem cell transplantation;
Prediction factors
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
Chimerism;
Female;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation;
Humans;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
Prognosis;
Retrospective Studies;
Young Adult
- From:
Chinese Journal of Hematology
2018;39(11):932-936
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the prognostic significance of early phase full donor chimerism (FDC) after myeloablative allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Methods: The clinical data of 72 hematological patients received myeloablative allo-PBSCT from Feb. 2016 to Jul. 2017 were analyzed retrospectively. The median age was 36.5 years (range 4-59), 44 were males and 28 females. Of the donors, there were 35 HLA matched sibling donors, 27 haploidentical donors and 10 unrelated donors. Polymerase chain reaction amplification of short tandem repeat sequence (PCR-STR) was used to detect donor cell chimerism (DC) rate of recipient bone marrow at one, two and three months after transplantation. Results: The median follow-up was 462 d (range: 47-805 d), 55 cases were still alive, and 45 cases were disease-free survival (DFS) at the end of follow-up. The 2-year overall survival (OS) and DFS were (68.9±7.7)% and (59.5±6.3)%, respectively. A number of 16 cases underwent relapses, with 2-year cumulative incidence of (24.1±5.3)%. The median time of recurrence was 157(32-374) d. Forty cases (55.6%) developed acute graft-versus-host diseases (aGVHD), with median time of 35.5 (13-90) d. Chronic GVHD (cGVHD) occurred in 23 patients (31.9%), with median time of 169 (94-475) d. Univariate analysis found the following factors were not related to OS, DFS or relapse rate (RR), including age, sex, blood type and sex of donor-recipient, occurrence of aGVHD and cGVHD. The OS and DFS in cases reached FDC and no FDC at two months after transplantation were (85.2±6.9)% vs (66.1±7.7)% (P=0.051) and (76.7±7.7)% vs (48.9±8.1)% (P=0.021), respectively. The RR rate in FDC group was lower than that in no FDC group [(16.6±6.8)% vs (30.4±7.8)%, P=0.187, respectively]. Conclusion: The present study confirmed the important value for predicting the prognosis with whether or not the patients reached FDC at the early phase after allo-PBSCT. The OS and DFS in cases with FDC at two months after transplantation were significantly higher than those of no FDC patients.
